|
IQVIA Inc
bbv152 vaccine  Bbv152 Vaccine, supplied by IQVIA Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/bbv152/pmc08584828-130-8-33?v=IQVIA+Inc Average 90 stars, based on 1 article reviews
bbv152 vaccine - by Bioz Stars,
2026-08
90/100 stars
|
Buy from Supplier |
|
BioNTech
bbv-152 Bbv 152, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/bbv152/10__22207_slash_jpam__16__2__47-12-5-14?v=BioNTech Average 90 stars, based on 1 article reviews
bbv-152 - by Bioz Stars,
2026-08
90/100 stars
|
Buy from Supplier |
|
AstraZeneca ltd
bbv152 Bbv152, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/bbv152/pmc09838840-91-30-31?v=AstraZeneca+ltd Average 90 stars, based on 1 article reviews
bbv152 - by Bioz Stars,
2026-08
90/100 stars
|
Buy from Supplier |
|
Bharat Biotech
bbv152 Bbv152, supplied by Bharat Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/bbv152/pmc11092912-253-0-1?v=Bharat+Biotech Average 86 stars, based on 1 article reviews
bbv152 - by Bioz Stars,
2026-08
86/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Lancet (London, England)
Article Title: Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
doi: 10.1016/S0140-6736(21)02000-6
Figure Lengend Snippet: Trial profile NP=nasopharyngeal. *Safety follow-up ongoing. †119 participants in the BBV152 group and 152 in the placebo group did not attend the day 84 visit but were not lost to follow-up or discontinued.
Article Snippet: The primary outcome was the efficacy of the
Techniques:
Journal: Lancet (London, England)
Article Title: Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
doi: 10.1016/S0140-6736(21)02000-6
Figure Lengend Snippet: Demographic characteristics of participants in the safety population (N=25 753)
Article Snippet: The primary outcome was the efficacy of the
Techniques:
Journal: Lancet (London, England)
Article Title: Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
doi: 10.1016/S0140-6736(21)02000-6
Figure Lengend Snippet: BBV152 vaccine efficacy against SARS-CoV-2 after at least 14 days after the second dose in the per-protocol population (N=16 973)
Article Snippet: The primary outcome was the efficacy of the
Techniques:
Journal: Lancet (London, England)
Article Title: Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
doi: 10.1016/S0140-6736(21)02000-6
Figure Lengend Snippet: SARS-CoV-2 neutralising antibody titres (MNT 50 assay) and binding antibody responses (ELISA; S1 protein, RBD, and N protein IgGs)
Article Snippet: The primary outcome was the efficacy of the
Techniques: Binding Assay, Enzyme-linked Immunosorbent Assay, Protein Binding
Journal: Lancet (London, England)
Article Title: Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
doi: 10.1016/S0140-6736(21)02000-6
Figure Lengend Snippet: Efficacy against variants of interest and variants of concern
Article Snippet: The primary outcome was the efficacy of the
Techniques: